转移性激素敏感前列腺癌的快速发展的治疗格局
Eun-Mi Yu1, Ishan Patel2, Min Woo Hwang3
1GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA.
Clinical Medicine Insights. Oncology
|September 26, 2024
概括
对转移性激素敏感前列腺癌 (mHSPC) 的单一治疗不再是最佳的. 前线双重和三重疗法现在是先进前列腺癌治疗的首选.
科学领域:
- 在瘤学瘤学.
- 医学科学 医学科学 医学科学
背景情况:
- 转移性激素敏感前列腺癌 (mHSPC) 的管理已经显著发展.
- 雄激素剥夺疗法 (ADT) 是历史上的标准,但新型药物已经出现.
- 最初批准用于转移性割抵抗性前列腺癌 (mCRPC) 的药物现在用于mHSPC.
研究的目的:
- 审查一线 de novo mHSPC 的不断变化的治疗环境.
- 探索最前沿的双重和三重疗法选择.
- 讨论支持FDA批准mHSPC治疗的关键试验.
主要方法:
- 审查前列腺癌治疗的最新进展.
- 对新型激素疗法,化疗和其他药物的临床试验数据的分析.
- 专注于第一线转移性割敏感前列腺癌 (mCSPC) 的治疗方法.
主要成果:
- 对于适合mCSPC患者来说,ADT单疗是不理想的.
- 新的激素疗法,化疗 (docetaxel,cabazitaxel) 和放射性连接剂已经改变了治疗方法.
- 越来越多地使用组合疗法 (双重和三重).
结论:
- 目前对mHSPC的治疗模式已经从ADT单疗转移.
- 前线组合疗法代表了符合条件的患者护理的新标准.
- 进一步的研究和临床试验继续改进mHSPC管理.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


